null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

-0.42x Total Debt / Equity (Negative equity)

Moderate-high sensitivity; JRSIS carries significant debt relative to thin margins, 200bps rate rise likely adds ~15-20% to interest expense, compressing already narrow net margins

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Southern China pharmaceutical manufacturing corridor and Hong Kong cross-border logistics gateway represent primary geopolitical chokepoints

Revenue concentrated in HKD and RMB markets; RMB devaluation risk is primary exposure, HKD peg provides partial buffer, minimal third-market diversification

Operations primarily in Hong Kong and mainland China; RMB depreciation pressure and HKD peg stress are top sovereign currency risks given near-total China-region concentration

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on select Chinese pharmaceutical distributors and licensed drug suppliers; likely one or two vendors exceed 30% of procurement input cost

Minimal cloud infrastructure dependency; JRSIS operates physical healthcare/pharmacy retail model, cloud termination would cause administrative disruption but not operational collapse

Limited secondary digital platform exposure; back-office ERP and billing systems would be impacted by cloud termination but core service delivery is clinic-based

Low API coupling risk; company relies on basic healthcare IT systems rather than deep third-party API integrations, switching cost is operational not architectural

Low Howey Test risk; primary revenue from healthcare services and pharmaceutical retail constitutes direct service exchange, not passive investment return scheme

Very High

Moderate; patient health data held in Hong Kong and China jurisdictions, limited GDPR/CCPA exposure due to minimal EU/US customer base, but China PIPL compliance is active risk

Low antitrust risk; JRSIS holds small market share in fragmented Hong Kong and China healthcare retail market, no dominant position to trigger regulatory scrutiny

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Predominantly transactional (~85-90%); healthcare consultations and pharmaceutical sales are episodic, with limited recurring contract or subscription revenue streams

Fee-for-service medical consultations and pharmaceutical product sales; essentially direct retail healthcare monetization with minimal platform or recurring revenue overlay

Weak pricing architecture; commodity pharmaceutical pricing constrained by Chinese government controls, service fees subject to competitive market pressure and thin differentiation

2/5 pricing power; operates in price-sensitive, regulated Hong Kong and China healthcare market with limited brand premium and strong substitutes from public hospitals

1.1% Gross Margin (Thin (<20%))

Moderate churn risk; no subscription lock-in, patients are transactional, no free-rider problem but high sensitivity to competing clinic proximity and pricing

Revenue growth is largely headcount-linear; adding clinics and pharmacy outlets requires proportional clinical and pharmacy staff, limiting operating leverage

High marginal cost of growth; each revenue increment requires physical clinic expansion, licensed medical staff, and regulatory approvals, sublinear scaling is not achievable near-term

Moderate; if operating franchise or licensed clinic model in China, regulatory drift risk is real given evolving Chinese healthcare licensing and cross-border practice rules

At 10x scale, CAC would rise sharply as geographic density increases; unit economics likely deteriorate without brand investment offsetting walk-in traffic dependence

Negligible network effects; healthcare retail is a local, relationship-based service with no meaningful data network, platform, or user-growth flywheel

-4.0% Return on Assets (Negative equity)

Tier 2 moderate resilience; essential healthcare services provide partial recession buffer, but discretionary wellness and elective consultations decline in downturns

Individual retail patients in Hong Kong and southern China seeking outpatient medical consultations and pharmaceutical products; predominantly self-pay or private insurance

Corporate health program clients and cross-border medical tourists from mainland China seeking Hong Kong-licensed medical services represent secondary but growing segment

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

0.0% CapEx / Revenue (Low-CapEx Asset-Light)

0001597892

JRSS